(Q45800633)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

title

Cytoplasmic expression of estrogen receptor beta (ERβ) predicts poor clinical outcome in advanced serous ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Giuseppe Vizzielli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

8

Giovanni Scambia

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Ilaria De Stefano

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Gian Franco Zannoni

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Maria Grazia Prisco

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Anna Fagotti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Luca Mencaglia

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Daniela Gallo

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

language of work or name

English

0 references

publication date

12 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

573-579

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

Estimates of the cancer incidence and mortality in Europe in 2006.

4 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

7 January 2021

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Hormone prevention strategies for breast, endometrial and ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Loss of ERbeta expression as a common step in estrogen-dependent tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen signaling: a subtle balance between ER alpha and ER beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen receptor beta2 and beta5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Combined analysis of estrogen receptor beta-1 and progesterone receptor expression identifies lung cancer patients with poor outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Changes in the expression of oestrogen receptors and E-cadherin as molecular markers of progression from normal epithelium to invasive cancer in elderly patients with vulvar squamous cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Membrane-associated estrogen receptor signaling pathways in human cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

The importance of ERbeta signalling in the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Optimal chemotherapy treatment for women with recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Current issues in ER and HER2 testing by IHC in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Assessment of multiple different estrogen receptor-beta antibodies for their ability to immunoprecipitate under chromatin immunoprecipitation conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Potential for false-positive staining with a rabbit monoclonal antibody to progesterone receptor (SP2): findings of the UK National External Quality Assessment Scheme for Immunocytochemistry and FISH highlight the need for correct validation of anti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Aberrant cytoplasmic expression of the p16 protein in breast cancer is associated with accelerated tumour proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Prognostic significance of estrogen receptor alpha and beta expression in human serous carcinomas of the ovary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Immunohistochemical comparison of primary peritoneal and primary ovarian serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen and progesterone receptors in ovarian epithelial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Validation of tissue microarray technology in ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Value of estrogen and progesterone receptor immunostaining in distinguishing between peritoneal mesotheliomas and serous carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen, progesterone and epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogens and epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen Receptor Subtypes in Ovarian Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Progesterone receptor isoforms A and B in human epithelial ovarian carcinoma: immunohistochemical and RT-PCR studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Beta3-tubulin is induced by estradiol in human breast carcinoma cells through an estrogen-receptor dependent pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Estrogen receptor beta in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

Selective estrogen receptor modulator medicinal chemistry at Merck. A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2011.05.025

10.1016/J.YGYNO.2011.05.025

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21665249%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference